More Big-name Pharma Firms Join NCATS Therapeutic Repurposing Effort | GenomeWeb

NEW YORK (GenomeWeb News) – The National Center for Advancing Translational Sciences said today that five additional pharmaceutical companies have joined its new program to enable researchers to study new uses for chemical compounds that have been set aside by drug makers

The five new participants in the NCATS program are Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutical Research and Development, and Sanofi.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Plasmodium knowlesi population structure, 'pre-adaptations' in algal ancestors of land plants, and more.

Replication studies that don't quite reflect the original findings underscore the need to better share data, the Wall Street Journal reports.

About two-thirds of proposals to work with select agents are denied — though most proposals that come in don't meet the definition of a restricted experiment, according to an analysis by the Centers for Disease Control and Prevention.

Researchers examine plant and human DNA found on the Shroud of Turin.